Natalya A. Nashivochnikova

Natalya A. Nashivochnikova

Auto-generated profile, based on publicly available information

Natalya A. Nashivochnikova

Privolzhsky Research Medical University

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 September 2023 in Experimental and Сlinical Urology
Verified
Journal Article
Open access
TRthe Department of Urology named after E.V. Shakhov of Privolzhsky Research Medical University Ministry of Health of Russia
the Department of Urology named after E.V. Shakhov of Privolzhsky Research Medical University Ministry of Health of Russia
NNN.A. Nashivochnikova
N.A. Nashivochnikova
RNRussia Nizhny Novgorod
Russia Nizhny Novgorod
Introduction. Chronic prostatitis (СР) is an inflammation of the prostate tissue, including non-infectious genesis. This is the most common urological disease in men under 50 years of age and the third most common in people over 50 years of age. A promising and actively studied direction of conservative therapy of the inflammatory process in the prostate gland is the use of drugs of animal origin based on prostate extract. The purpose.This work is devoted to the comparative characteristics of drugs with prostate extract effectiveness in the complex therapy of patients with chronic prostatitis. Materials and methods. Retrospective analysis of medical records of 125 patients with a previously established diagnosis of СР of the II and IIIA, and IIIB categories aged from 22 to 55 years was performed. Depending on the preparation used with prostate extract in the complex therapy of CP, patients were divided into 5 groups. Preparations with prostate extract were used for 20 days. The effectiveness analysis included an assessment of the dynamics of the clinical picture, the results of laboratory and instrumental research methods, as well as questionnaire data on valid questionnaires I-PSS (International System for the Summary Assessment of Prostate Diseases, Lower Urinary Tract Symptoms (LUTS)), IIEF-15 (International Index of Erectile Function), NIH Chronic Prostatitis symptom Scale- CPSI. Results. The analysis of the results showed that the use of Vitaprost® in the complex therapy of СР is accompanied by a decrease in the number of leukocytes in the analysis of prostate secretion, positive dynamics in relation to the total score of the severity of pain syndrome and the patient's assessment of his condition on the NIH-CPSI scale of symptoms of chronic prostatitis, which may indicate a decrease in the inflammatory process in the prostate in general. The effectiveness of therapy in relation to erectile function on the IIEF-15 scale, reduction in the severity of symptoms on the IPSS scale and positive dynamics in relation to urination parameters was also noted. Conclusion. According to the results of the work carried out, it was the use of Vitaprost® that was accompanied by a significant decrease in the symptoms of CP and an improvement in the quality of life of patients, as well as erectile function of patients, an increase in the flow rate of urine, a decrease in the volume of residual urine and intensiveness of inflammation.

15 December 2021 in Urology Reports (St. - Petersburg)
Verified
Journal Article
Closed access
PDF file
VKValentin N. Krupin
Valentin N. Krupin
NNNatalya A. Nashivochnikova
Natalya A. Nashivochnikova
MUMikhail N. Uezdnyj
Mikhail N. Uezdnyj
BACKGROUND: The study of the relationship between the presence of varicocele and male infertility is the subject of numerous studies, while many aspects of impaired spermatogenesis remain unclear. It has been established that after surgical treatment of varicocele, fertility is not restored in a significant number of patients. In this regard, the search for new and pathogenetically substantiated methods of treating such patients seems to be very relevant. AIM: To evaluate the effectiveness of antioxidant therapy in spermatogenesis disorders in men with varicocele, prescribed both in combination with surgery and as monotherapy. MATERIALS AND METHODS: Three groups of infertile men with varicocele were observed, who were treated with Speroton (a complex containing folic acid, L-carnitine, zinc, selenium, vitamin E) 1 sachet once a day, the duration of the course was three months. Patients of the first group (n = 43) were prescribed the drug after the Ivanissevich operation, the patients of the second group (n = 37) received antioxidant therapy during three months before the Ivanissevich operation and continued for three months after it. Patients of the third group (n = 21) did not undergo surgery, but received only antioxidant therapy for six months. The results of the combined treatment and conservative therapy with Speroton were compared with the results of treatment of 65 infertile patients who underwent only Ivanissevichs operation. RESULTS: In patients with varicocele with initially pathological parameters of ejaculate, who were prescribed drugs with antioxidant properties in the postoperative period as an adjuvant treatment for 3 months, in 76.7% of cases there was a change in spermogram indicators towards improvement. The most significant changes were observed six months after the operation and subsequent adjuvant therapy. The indicators characterizing sperm motility underwent more noticeable changes. In patients who received only antioxidant therapy for six months, in all cases, there was a statistically significant (p 0.001) improvement in sperm motility, which persisted for six months and exceeded these changes in groups of patients with adjuvant therapy and neo- and adjuvant therapy. CONCLUSIONS: The results obtained allow us to conclude that there is no need for surgical treatment for varicocele in order to treat male infertility, since the operation itself can negatively affect the state of spermatogenesis, and conservative antioxidant therapy leads to better results in infertility treatment than the performed operation or any combination of it with antioxidant therapy.

12 September 2022 in Andrology and Genital Surgery
Verified
Journal Article
Open access
PDF file
PKP. S. Kyzlasov
P. S. Kyzlasov
EGE. S. Gubanov
E. S. Gubanov
ЕГЕ. А. Гринь
Е. А. Гринь
NNN. A. Nashivochnikova
N. A. Nashivochnikova
SKS. S. Krasnyak
S. S. Krasnyak
Background. Peyronie’s disease is a disease characterized by chronic inflammation of the protein membrane of the fibrous tissue of the penis. Oral pharmacotherapy allows a long-term effect on the mechanisms of formation of fibrous plaque. Aim. To evaluate the degree of change in complaints against the background of the complex drug Peyroflex ® and its effectiveness. Materials and methods. The study was conducted as a prospective observational study. The study included 43 patients with complaints of pain in the penis area during erection or at rest, curvature of the penis, the presence of palpable plaque in the area of the cavernous bodies. Men took Peyroflex ® on a regular basis, one capsule (410 mg) 2 times a day for 6 months or until the pain disappeared during erection, but not less than 6 months. Results. The intensity of pain after 3 and 6 months of taking Peyroflex ® decreased by 47.8 and 78.3 %, respectively. The severity of penile curvature showed a tendency to decrease by 7.5 % after 3 doses of Peyroflex ® and remained stable after 6 months. The plaque area according to the results of ultrasound examination after 3 and 6 months of taking Peyroflex ® decreased by 14.7 and 17.2 %, respectively. Conclusion. Peyroflex ® can be recommended for use in the active phase of Peyronie’s disease both in monotherapy and in combination with other methods of treatment (extracorporeal shock wave therapy, physiotherapy, etc.).

30 December 2025 in Urology Reports (St. - Petersburg)
Verified
Journal Article
Closed access
AKAleksei V. Krupin
Aleksei V. Krupin
VKValentin N. Krupin
Valentin N. Krupin
FSFedor A. Sevryukov
Fedor A. Sevryukov
OMOleg E. Makarov
Oleg E. Makarov
NNNatalya A. Nashivochnikova
Natalya A. Nashivochnikova
IUIgor B. Ulitin
Igor B. Ulitin
BACKGROUND: Impaired blood supply to the bladder is considered a risk factor for urinary dysfunction, including in patients with benign prostatic hyperplasia. One of the possible causes of pelvic hemodynamic disturbances is hypertension. AIM: This study aimed to evaluate the impact of hypertension on the severity of lower urinary tract symptoms in patients with benign prostatic hyperplasia. METHODS: This retrospective and prospective observational study included 6117 men aged 48 to 83 years (mean age: 59.57 ± 10.1 years) who underwent surgical treatment for benign prostatic hyperplasia; 5960 patients were included in the final analysis. Medical records were reviewed with assessment of International Prostate Symptom Score, ultrasonographic findings of the prostate and bladder, and the presence and characteristics of comorbid conditions. RESULTS: Hypertension was identified in 3052 (51.2%) patients, of whom only 1385 (45.4%) were aware of the diagnosis. Patients with benign prostatic hyperplasia and concomitant hypertension demonstrated greater severity of lower urinary tract symptoms, with significant differences observed not only in overall International Prostate Symptom Score but also separately for storage and voiding symptoms. The severity of urinary dysfunction, primarily storage symptoms, depended on the stage and duration of hypertension, as well as on pharmacological blood pressure control. The presence of hypertension influenced the likelihood of persistent urinary dysfunction after surgical treatment of benign prostatic hyperplasia. In the postoperative period, lower urinary tract symptoms were observed in 2078 (68.1%) of 3052 patients with hypertension, compared with only 577 (19.8%) of 2908 patients without hypertension. CONCLUSION: Hypertension is associated with increased severity of lower urinary tract symptoms in patients with benign prostatic hyperplasia; the duration and stage of hypertension, as well as antihypertensive therapy, are of significance. Hypertension may be considered a risk factor for persistent lower urinary tract symptoms in the long-term postoperative period. Prior to deciding on surgical intervention for benign prostatic hyperplasia in patients with hypertension, adequate blood pressure control followed by reassessment of lower urinary tract symptom severity appears to be necessary.

25 March 2024 in Experimental and Сlinical Urology
Verified
Journal Article
Open access
IKIbishev Kh.S.
Ibishev Kh.S.
NNNashivochnikova N.A.
Nashivochnikova N.A.
TATsareva A.V.
Tsareva A.V.
SIShaderkin I.A.
Shaderkin I.A.
KSKrasnyak S.S.
Krasnyak S.S.
RRRussia Rostov-On-Don
Russia Rostov-On-Don
Introduction. Cystitis is one of the most prevalent urinary tract infection (UTI) type. An important specifity of cystitis is the tendency to relapse and chronization of the disease. The search for a

15 June 2026 in Лечащий врач
Verified
Journal Article
Closed access
NNN.A. Nashivochnikova
N.A. Nashivochnikova
VKV.N. Krupin
V.N. Krupin
SZS.YU. Zubova
S.YU. Zubova
VLV.E. Leanovich
V.E. Leanovich
Background. The incidence of urogenital disorders in women aged 55-70 years reaches 30-75%. This is a complex of vaginal and urinary symptoms, the development of which is a complication of age-related processes in estrogen-dependent tissues and structures of the lower urinary tract and reproductive tract. Objective. To study the effectiveness of the dietary supplement, containing a complex of natural plant substances – D-mannose, cranberry type A proanthocyanidins and vitamin C, in patients with recurrent lower urinary tract infections during the postmenopausal period. Materials and methods. The study included 90 postmenopausal patients with recurrent urinary tract infection. The main group consisted of 46 patients, the control group – 44 patients (average age 59.3 ± 5.3 years). Patients of the main group were prescribed antimicrobial therapy for exacerbations (fosfomycin trometamol in a dose of 3 g once) + dietary supplement Cystenium II, containing a complex of natural plant substances, which was used 1 tablet 2 times a day with meals for 3 months. Patients in the control group received standard antimicrobial therapy in case of exacerbation of urinary tract infection. The results were assessed 1 month after the start of therapy and 6 months later. Results. During the study, all patients of the main group (46 women), who used the Cystenium II dietary supplement as part of treatment, together with antimicrobial therapy during an exacerbation of infection, noted a significant improvement in both general well-being and local symptoms not only at visits 1 month after the start of taking the drug, but also during the entire observation period after 6 months. As a result of the active anti-inflammatory, protective action, and the presence of vascular effects of the components of the dietary supplement, not only the general condition of the patients improved, according to LDF data, positive dynamics were noted at the level of microcirculation of the tissues of the bladder wall and urethra and, as shown by ultrasound Dopplerography, venous congestion in the pelvic organs and paraurethral plexus is reduced. The use of the dietary supplement allowed not only to significantly reduce the rate of asymptomatic bacteriuria among women in the main group, but also the number of relapses of cystitis over 6 months of observation from the start of therapy. An important predisposing factor in the development of recurrent urinary tract infection in postmenopausal women is the state of the hormonal background, which entails metabolic, local immune changes, and disorder of pelvic hemodynamics as a whole. Adequate blood supply, including venous, is also one of the main prerequisites for the normal functional activity of the mucous membrane of the urogenital area and bladder. The active components included in the dietary supplement not only help improve the hemodynamics of the bladder and urethra, but also have a protective, anti-inflammatory effect, as evidenced by a 4-fold decrease in the number of urinary tract infection relapses in patients of the main group over 6 months of observation. Conclusion. The results obtained indicate the high therapeutic effectiveness of the dietary supplement, containing a complex of natural plant substances, both for complex therapy and for the prevention of relapses of lower urinary tract infections in patients, including during the postmenopausal period.